TVM Capital Promotes Dr. Jens W. Eckstein to Partner.

BOSTON -- TVM Capital, a venture capital firm focusing on investments in life sciences and information technology, and with offices in Boston and Munich, today announced the promotion of Dr. Jens W. Eckstein to partner, effective January 1, 2007.

Dr. Eckstein joined TVM Capital's life sciences practice in 2004, based in the firm's Boston office. He currently focuses on early stage life sciences investments, and is actively involved in TVM Capital's investments in CoNCERT Pharmaceuticals, Magen BioSciences, SelectX Pharmaceuticals, and Sirtris Pharmaceuticals. Additionally, he acts as an advisor to portfolio companies Magen and Sirtris.

"Jens has been a valuable asset to TVM Capital and our life sciences portfolio companies," said Dr. Helmut M. Schuhsler, managing partner for TVM Capital. "His experience in multiple scientific disciplines, combined with his deep drug discovery and development knowledge, has earned him numerous industry accolades and tremendous respect from his colleagues here at TVM Capital. We look forward to continuing to leverage his expertise to drive growth in our life sciences portfolio."

Prior to joining TVM Capital, Dr. Eckstein was director of lead discovery and research IT at Enanta Pharmaceuticals, Inc., directing the company's discovery and knowledge management programs for novel therapeutics in hepatitis, asthma, psoriasis and other autoimmune disorders. He also worked for Mitotix (now GPC-Biotech) where he managed research groups in biochemistry, structural biology, and computational chemistry. He also led the company's $48 million research collaboration with the BASF Bioresearch Corporation (BBC) on Cdc25 anticancer therapeutics.

Dr. Eckstein earned his doctorate, summa cum laude, in biological chemistry at the University of Konstanz and Harvard University. He was a postdoctoral fellow at the University of California in San Francisco (UCSF). The author of more than 20 scientific publications, Dr. Eckstein also holds several issued patents. He is managing editor of Frontiers in Bioscience "Current Topics in Lead Discovery" and serves as an editorial board advisor for IDrugs. Dr. Eckstein is an Advisor to the Alzheimer Research Forum (ARF) and a founding member of the Cure Dystonia Initiative Advisory Council (CDIAC). He is also currently a Kauffman Fellow (www.kauffmanfellows.org).

About TVM Capital

TVM Capital was founded in 1983 as one of the first venture capital firms formed in Germany, and an early entrant into the U.S. market in 1986. Since inception TVM Capital has raised over $1.6 billion in six fund generations and has established itself as a leading life sciences and technology investment group in the U.S. and Europe. TVM Capital funds have made investments in more than 220 life sciences and information technology companies where innovation, effective management and sound financial backing have enormous impact on company growth. TVM's in-depth knowledge of the U.S. and European environments helps companies create businesses that enjoy access to science, management talent, distribution channels and capital on both sides of the Atlantic. More than 40 companies have gone public on U.S. or European stock exchanges. Today, TVM Capital is actively invested in more than 60 companies. Current life sciences investments include CoNCERT Pharmaceuticals, Magen Biosciences, Proteon Therapeutics, SelectX Pharmaceuticals and Sirtris Pharmaceuticals. Visit www.tvm-capital.com for more information.